Dronabinol
Product Description
Benuvia-CDMO
-
Country/Region:United States
-
On CPHI since:2025
-
Certificates:3
-
Employees:50 - 99
Company types
Primary activities
Categories
Specifications
Benuvia-CDMO
-
Country/Region:United States
-
On CPHI since:2025
-
Certificates:3
-
Employees:50 - 99
Company types
Primary activities
Benuvia-CDMO resources (2)
-
News Benuvia Operations supports FDA IND filing by Mandara Biopharma for dronabinol oral solution in Alzheimer's Agitation
Benuvia Operations, LLC (Benuvia), a U.S.-based pharmaceutical development and manufacturing company specializing in regulated and controlled-substance drug products and active pharmaceutical ingredients (APIs), today announced its role as manufacturing partner supporting Mandara Biopharma Inc.’s (Mandara) filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate clinical development of a dronabinol oral solution formulation for the treatment of agitation associated with Alzheimer’s disease.
The dronabinol oral solution formulation was developed by Benuvia and licensed to Mandara under an exclusive agreement. Under the collaboration, Benuvia will serve as Mandara’s manufacturing partner for the clinical and potential commercial supply of the product.
-
Brochure CS_Delivering Scalable Manufacturing with Increased Stability and Reduced Costs
How Benuvia Revolutionized Psilocin and Psilocybin Production.